Antibody-containing solution pharmaceuticals

Abstract

An antibody-containing solution formulation comprising an organic acid and a surfactant as stabilizers; a method for suppressing the formation of visible insoluble matter and / or insoluble particles due to the presence of metal ions in an antibody-containing solution formulation, which comprises adding an organic acid to the solution; a method for suppressing the formation of visible insoluble matter and / or insoluble particles during shaking and freezing-thawing of an antibody-containing solution, which comprises adding a surfactant to the solution; and a method for stabilizing an antibody-containing solution, which comprises adding an organic acid and a surfactant.

Description

TECHNICAL FIELD [0001] The present invention relates to stable solution formulations containing antibodies. BACKGROUND ART [0002] Advances in gene recombination technology have enabled the pharmaceutical use of antibodies such as immunoglobulins, monoclonal antibodies and humanized antibodies. To ensure a stable supply of these antibodies, it is necessary to establish production and storage conditions where the structure and activity of the antibodies can be maintained. [0003] When proteins are stored in a highly concentrated solution form, they are usually associated with a problem of deterioration, including the formation of insoluble aggregates, which is required to be prevented. It is necessary to prevent such deterioration. For example, the applicant has found that an anti-HM1.24 antibody has a therapeutic effect on myeloma cells (JP KOKAI 11-092399), and also has studied formulation of this antibody. However, the anti-HM1.24 antibody is an unstable protein and is more likely t...

AI Technical Summary

Benefits of technology

[0009] The object of the present invention is to provide an antibody-containing solution formulation that is stable for long-term storage. This formulation is designed to suppress the formation of visible insoluble matter and / or insoluble particles, which are derived from the aggregation of antibodies caused by physical stresses (e.g., freezing-thawing) during its production process and by long-term storage; and to suppress the formation of visible insoluble matter and / or insoluble particles in the presence of metal ions (Fe ions) introduced during the production process.

[0010] As a result of extensive and intensive efforts made to achieve the above object, the inventors of the present invention have found that the use of organic acids significantly suppresses the formation of visible insoluble matter in the presence of iron, and that the addition of surfactants very significantly suppresses the formation of visible insoluble matter and / or insoluble particles during shaking and freezing-thawing steps. These findings have led to the completion of the present invention.

Problems solved by technology

When proteins are stored in a highly concentrated solution form, they are usually associated with a problem of deterioration, including the formation of insoluble aggregates, which is required to be prevented.

However, the anti-HM1.24 antibody is an unstable protein and is more likely to undergo physical and chemical changes (e.g., association, aggregation) as a result of stresses in the purification process.

However, repeating such shaking and freezing-thawing steps causes the formation of antibody aggregates and / or insoluble particles.

Furthermore, long-term storage causes decomposition of antibodies, resulting in formation of decomposition products.

There is also a problem that visible insoluble matter and insoluble particles are formed in the presence of metal ions (Fe ions) introduced during the production process.

However, there is a limit to removal methods such as precipitation, complex formation, and so on.

However, when added as stabilizers, organism-derived high-molecular weight materials like proteins are disadvantageous in that very complicated processes are required to remove contaminants, such as viruses and prions.

Images